Reaction Biology CorpReaction Biology Corp. ("RBC") was founded to pursue new economies in HTS and bio-chemical assays. RBC offers outsourced screening, proiling, and assay development, at lower cost than traditional outsourcing labs. RBC also performs NIH-funded research in technology development and early stage drug discovery.
Screening partnerships with industry partners are also part of the RBC portfolio.
RBC specializes in developing new nanoliter scale assaying methods. By carefully scaling down enzyme and compound volume, RBC is able to offer outsourced biochemical assays at a much more economical price than other outsource or even in-house labs.
RBC's scientists have carefully studied the effects of miniaturization on standard assays, and have selected the latest technology to maintain high levels of repeatability and low error rates. RBC utilizes a proprietary suite of techniques in its low volume assays. While various low-volume technologies have been available for some time, their combination must be carefully researched in order to maximize eficiencies and minimize error rates. RBC has achieved what discovery researchers prize most: excellent data quality at low cost.
RBC ServicesRBC offers a suite of services for early stage drug discovery that can allow researchers to expand their discovery horizons while controlling, even reducing, budgetary expenditures.
Download the RBC Services in pdf format » |
|
